The P2Y12 Inhibitors Market in the U.S. is primarily used for the treatment of cardiovascular disorders such as acute coronary syndrome (ACS) and coronary artery disease (CAD). P2Y12 inhibitors function by inhibiting platelet activation and aggregation which prevents blood clots formation. The market comprises oral antiplatelets including clopidogrel, ticagrelor and prasugrel which help in preventing stent thrombosis in patients undergoing PCI or CABG.
The Global U.S. P2Y12 Inhibitors Market is estimated to be valued at US$ 267.73 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 To 2031. Demand for oral P2Y12 inhibitors is increasing owing to high prevalence of cardiovascular diseases, rising number of PCI procedures and increasing adoption of drug eluting stents in cardiac revascularization.
Key Takeaways
Key players operating in the U.S. P2Y12 Inhibitors are Abcam plc, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation. The key players are involved in developing and commercializing drugs and diagnostic kits for cardiovascular diseases.
The U.S. P2Y12 Inhibitors Market Size is witnessing high growth owing to increasing prevalence of cardiovascular diseases in the country. As per recent data, over 121 million Americans are currently living with some form of cardiovascular disease. Growing geriatric population, sedentary lifestyle and risk factors like diabetes, obesity are fueling the incidence of cardiovascular disorders.
Technological advancements in the field of drug-eluting stents, strong pipeline of P2Y12 inhibitors with improved safety profiles are expected to drive the growth of the market. Ongoing clinical trials evaluating newer antiplatelets for efficacy in reducing major adverse cardiac events are widening the treatment options.
Market Trends
Increased usage of drug-eluting stents: Drug eluting stents have largely replaced bare metal stents due to associated lower restenosis rates. This has boosted the overall adoption of antiplatelet therapies including P2Y12 inhibitors in cardiology practice.
Higher efficacy antiplatelets: Newer P2Y12 inhibitors ticagrelor and prasugrel have demonstrated better efficacy over clopidogrel in reducing major adverse cardiac events post PCI. This has shifted treatment guidelines in favor of ticagrelor and prasugrel over clopidogrel.
Market Opportunities
Undertreated patient population: It is estimated that over 80% of eligible patients discontinue P2Y12 inhibitor therapy within 1 year of being prescribed. Improving medication adherence can unlock significant market potential.
Pipeline drugs: New antiplatelets with rapid onset of action, fewer drug-drug interactions and easier dosing regimen can improve clinical outcomes. Drugs in clinical trials offer lucrative growth opportunities.
Impact of COVID-19 on U.S. P2Y12 Inhibitors Market:
The COVID-19 pandemic has had a major impact on the U.S. P2Y12 Inhibitors market growth. In the early stages of the pandemic, the governments imposed lockdowns which led to disruptions in manufacturing and supply chain activities. This significantly reduced the production and availability of P2Y12 inhibitors in the market. The demand also witnessed a decline as non-emergency medical procedures and elective surgeries were put on hold to free up healthcare resources for COVID-19 patients.
As the pandemic continues, the market has started recovering gradually. The manufacturers have resumed operations while following strict safety protocols. However, production is still running at sub-optimal levels due to labor shortages, logistical challenges and raw material constraints. The demand has improved from the lows of 2020 but is still below pre-pandemic levels as many hospitals continue to postpone non-urgent care.
To sustain growth in the long run, manufacturers will need to focus on ramping up manufacturing capacity, diversifying supply chains and building strategic inventory levels. Telehealth and digital solutions can help drive demand to some extent. However, a complete recovery of the market is dependent on overcoming the pandemic through vaccination drives and therapeutics.
Geographical Concentration:
In terms of value, the Northeast region accounts for the largest share of the U.S. P2Y12 Inhibitors market currently. States like New York, New Jersey, Pennsylvania and Massachusetts have a high concentration of hospitals, clinics and research institutes actively utilizing P2Y12 inhibitors.
Fastest Growing Region:
The South region is expected to witness the fastest growth in the U.S. P2Y12 Inhibitors market during the forecast period. This can be attributed to factors like rising healthcare expenditure, growing geriatric population susceptible to cardiovascular diseases, expanding medical infrastructure and increasing focus on research. States like Texas, Florida and North Carolina are emerging as hotspots for future market opportunities.
Get more insights on This Topic- U.S. P2Y12 Inhibitors Market
